These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28901484)

  • 1. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
    Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
    Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
    Tsou SH; Chen TM; Hsiao HT; Chen YH
    PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
    Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
    J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.
    Alfaro Y; Delgado G; Cárabez A; Anguiano B; Aceves C
    Mol Cancer; 2013 May; 12():45. PubMed ID: 23705792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
    Calaf GM; Ponce-Cusi R; Abarca-Quinones J
    Oncol Rep; 2018 Jun; 39(6):2741-2748. PubMed ID: 29693159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts.
    Mendieta I; Nuñez-Anita RE; Nava-Villalba M; Zambrano-Estrada X; Delgado-González E; Anguiano B; Aceves C
    BMC Cancer; 2019 Mar; 19(1):261. PubMed ID: 30902074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
    Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
    Chen JM; Bai JY; Yang KX
    IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression.
    De U; Chun P; Choi WS; Lee BM; Kim ND; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2014 Jan; 44(1):167-76. PubMed ID: 24190517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CD44
    Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
    Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
    Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
    Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
    Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
    Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB; Shen ZL; Fu J; Xu LZ
    Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
    Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
    BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines.
    Fu P; Du F; Chen W; Yao M; Lv K; Liu Y
    Oncol Rep; 2014 Jun; 31(6):2561-8. PubMed ID: 24737252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
    Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
    Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.